Cargando…

Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects

BACKGROUND: Telomerase and telomerase reverse transcriptase (hTERT) confer cancer cells sustained proliferation and survival potentials. Targeting telomerase or hTERT is a novel anti-cancer strategy. However, telomerase/hTERT inhibition alone has minimal clinical efficacy. We explored the relationsh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, T, Liang, X, Li, B, Björkholm, M, Jia, J, Xu, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681031/ https://www.ncbi.nlm.nih.gov/pubmed/23681187 http://dx.doi.org/10.1038/bjc.2013.208

Ejemplares similares

Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells
por: Strillacci, A, et al.
Publicado: (2010)

Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines
por: Uziel, O, et al.
Publicado: (2005)

Reptin is required for the transcription of telomerase reverse transcriptase and over-expressed in gastric cancer
por: Li, Wenjuan, et al.
Publicado: (2010)

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
por: Pichot, C S, et al.
Publicado: (2009)

CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer
por: Bronger, Holger, et al.
Publicado: (2016)

Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents
por: Saha, M N, et al.
Publicado: (2014)

Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer
por: Barnes, N L P, et al.
Publicado: (2007)

Radiation-enhancement of MDA-MB-231 breast cancer cell invasion prevented by a cyclooxygenase-2 inhibitor
por: Paquette, B, et al.
Publicado: (2011)

RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells
por: Strillacci, A, et al.
Publicado: (2006)

Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation
por: Boykin, C, et al.
Publicado: (2011)

COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia
por: Farooqui, M, et al.
Publicado: (2007)

H1/pHGFK1 nanoparticles exert anti-tumoural and radiosensitising effects by inhibition of MET in glioblastoma
por: Zhang, Wenyan, et al.
Publicado: (2018)

Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells
por: Valenzuela, M, et al.
Publicado: (2014)

Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo
por: Weiss, C, et al.
Publicado: (2012)

BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation
por: Hennig, R, et al.
Publicado: (2008)

Telomerase Reverse Transcriptase Synergizes with Calorie Restriction to Increase Health Span and Extend Mouse Longevity
por: Vera, Elsa, et al.
Publicado: (2013)

Imaging telomerase reverse transcriptase expression in oligodendrogliomas using hyperpolarized δ-[1-(13)C]-gluconolactone
por: Batsios, Georgios, et al.
Publicado: (2023)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma
por: Wong, E T, et al.
Publicado: (2015)

Telomerase reverse transcriptase and neurodegenerative diseases
por: Yu, Xin, et al.
Publicado: (2023)

Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
por: Andersson, Y, et al.
Publicado: (2009)

COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer
por: Timoshenko, A V, et al.
Publicado: (2006)

In vitro and in vivo reversal of resistance to 5-fluorouracil in colorectal cancer cells with a novel stealth double-liposomal formulation
por: Fanciullino, R, et al.
Publicado: (2007)

Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase
por: Maida, Yoshiko, et al.
Publicado: (2015)

Suppression of telomerase reverse transcriptase (hTERT) expression in differentiated HL-60 cells: regulatory mechanisms
por: Xu, D, et al.
Publicado: (1999)

Deciphering the Functions of Telomerase Reverse Transcriptase in Head and Neck Cancer
por: Yeh, Tsung-Jang, et al.
Publicado: (2023)

Targeting de novo lipogenesis as a novel approach in anti-cancer therapy
por: Stoiber, Katharina, et al.
Publicado: (2018)

SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response
por: Cheetham, S, et al.
Publicado: (2008)

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
por: Shimokawa, T, et al.
Publicado: (2012)

miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer
por: Shen, Y, et al.
Publicado: (2013)

In vivo and in vitro properties of STX2484: a novel non-steroidal anti-cancer compound active in taxane-resistant breast cancer
por: Stengel, C, et al.
Publicado: (2014)

BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML
por: Lin, W-H, et al.
Publicado: (2012)

Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer
por: Nitzsche, B, et al.
Publicado: (2012)

A functional bioassay to determine the activity of anti-VEGF antibody therapy in blood of patients with cancer
por: Wentink, Madelon Q, et al.
Publicado: (2016)

Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states
por: Yoshida, T, et al.
Publicado: (2014)

Telomerase reverse transcriptase in the regulation of gene expression
por: Zhou, Junzhi, et al.
Publicado: (2014)

Telomerase Reverse Transcriptase Regulates microRNAs
por: Lassmann, Timo, et al.
Publicado: (2015)

Implications of telomerase reverse transcriptase in tumor metastasis
por: Zou, Yongkang, et al.
Publicado: (2020)

Human recombinant anti-thyroperoxidase autoantibodies: in vitro cytotoxic activity on papillary thyroid cancer expressing TPO
por: Rebuffat, S A, et al.
Publicado: (2010)

Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer
por: Augustine, T A, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6c3ueln3n3hen5b9lcqb4jug9v